Preventing Hepatitis B Reactivation During Anti‐CD20 Antibody Treatment in the Veterans Health Administration

Preventing Hepatitis B Reactivation During Anti‐CD20 Antibody Treatment in the Veterans Health Administration

Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti‐cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti‐CD20 Ab therapy averts hepatitis, chemotherapy disruption, and death. Serologic evidence of prior HBV exposure is...

Full description

Bibliographic Details
Main Authors: A. Jasmine Bullard, Francesca E. Cunningham, Bryan D. Volpp, Elliott Lowy, Lauren A. Beste, Bernadette B. Heron, Mark Geraci, Julia M. Hammond, Kourtney LaPlant, Elise A. Stave, Marsha J. Turner, Meghan C. O’Leary, Michael J. Kelley, Christine M. Hunt
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2018-09-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1238

Internet

https://doi.org/10.1002/hep4.1238

Similar Items